Chemify, a deep-tech company that integrates chemistry, robotics, and AI to digitally design, discover, and synthesize new molecules, has announced the appointment of Kevin McGowan, PhD, MBA, as Chief Business Officer (CBO). McGowan, an expert in pharmaceutical business development, platform technology strategy, and sales and marketing, will lead Chemify’s efforts to scale commercialization and expand into U.S. markets.
Dr. Lee Cronin, CEO of Chemify, said, “Kevin’s expertise in platform technology development in the biopharma industry will help us expand our business operations and accelerate our growth, particularly in the U.S. We are excited to welcome him to the team.”
McGowan previously served as VP of BioPharma Growth at Blink Health, where he built pharmaceutical partnerships through BlinkRx. He also held the position of SVP of Commercial at Evozyne, driving business development and strategic initiatives in therapeutics and sustainability. His experience includes being an Associate Partner at McKinsey & Company, advising clients in specialty chemicals, advanced materials, and life sciences. McGowan holds an MBA from Duke University, a PhD in Chemistry from the University of Florida, and a BS in Chemistry from Duke University.
McGowan commented, “Chemify is at the forefront of digitizing and automating chemistry, revolutionizing chemical innovation. Our platform transforms small molecule R&D, enabling partners to discover drugs and materials more efficiently and rapidly.”
Chemify’s Chemputation technology addresses the slow, complex, and costly traditional methods of molecule and material synthesis. By combining decades of chemistry expertise with hardware robotics and AI, Chemify offers a comprehensive workflow for molecular discovery, optimization, and synthesis, accelerating advancements in medicine and advanced materials.
